Metri Bio is a biotechnology company developing first-in-class, disease‑modifying therapeutics that target the endometrium and related uterine tissues. The company focuses on endometriosis and other uterine diseases where current treatments are limited and reliable targets are lacking.

Metri Bio builds translational platforms to discover and validate targets and advance targeted therapeutics aimed at improving the lives of people affected by endometrial disease.

Metri Bio is co‑founded and led by CEO Ashley Abel, PhD (selected for Forbes 30 Under 30). Its scientific leadership and advisors include academic and clinical experts in genetics, obstetrics/gynecology, and reproductive biology.

The company announced a $5M pre‑seed raise to develop endometriosis therapeutics and lists backing from investors including Pillar, Pace Ventures, Slocum Management, and Navec. Prospective candidates can sign up on the careers page to be notified of open roles.